Treatments:Dipeptidyl Peptidase-4 Inhibitor Pharmacokinetics

From Proteopedia

Jump to: navigation, search

References for Dipeptidyl Peptidase-4 Inhibitor Pharmacokinetics[1][2][3][4][5][6][7][8]

  1. ↑ Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug;12(8):648-58. PMID:20590741 doi:10.1111/j.1463-1326.2010.01212.x
  2. ↑ Augeri DJ, Robl JA, Betebenner DA, Magnin DR, Khanna A, Robertson JG, Wang A, Simpkins LM, Taunk P, Huang Q, Han SP, Abboa-Offei B, Cap M, Xin L, Tao L, Tozzo E, Welzel GE, Egan DM, Marcinkeviciene J, Chang SY, Biller SA, Kirby MS, Parker RA, Hamann LG. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005 Jul 28;48(15):5025-37. PMID:16033281 doi:10.1021/jm050261p
  3. ↑ Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazoli n-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther. 2008 Apr;325(1):175-82. Epub 2008 Jan 25. PMID:18223196 doi:10.1124/jpet.107.135723
  4. ↑ Hu P, Yin Q, Deckert F, Jiang J, Liu D, Kjems L, Dole WP, He YL. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. J Clin Pharmacol. 2009 Jan;49(1):39-49. Epub 2008 Oct 1. PMID:18832295 doi:10.1177/0091270008325152
  5. ↑ Gupta R, Walunj SS, Tokala RK, Parsa KV, Singh SK, Pal M. Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Curr Drug Targets. 2009 Jan;10(1):71-87. PMID:19149538
  6. ↑ Bergman AJ, Cote J, Yi B, Marbury T, Swan SK, Smith W, Gottesdiener K, Wagner J, Herman GA. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care. 2007 Jul;30(7):1862-4. Epub 2007 Apr 27. PMID:17468348 doi:10.2337/dc06-2545
  7. ↑ He H, Tran P, Yin H, Smith H, Batard Y, Wang L, Einolf H, Gu H, Mangold JB, Fischer V, Howard D. Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos. 2009 Mar;37(3):536-44. Epub 2008 Dec 15. PMID:19074975 doi:10.1124/dmd.108.023010
  8. ↑ AstraZeneca & Bristol-Myers Squibb, An Open-label, Pharmacokinetic Study of Single and Multiple Doses of 5 mg Saxagliptin in Healthy Chinese Subjects Living in China, Study Code D1680C00004, 2009.

Proteopedia Page Contributors and Editors (what is this?)

David Canner

Retrieved from "http://proteopedia.org/wiki/index.php/Treatments:Dipeptidyl_Peptidase-4_Inhibitor_Pharmacokinetics"
Personal tools